Lewes, DE -- (SBWIRE) -- 07/10/2014 -- Despite mostly targeting established molecules, the psoriasis pipeline is showing a high level of innovation in first-in-class molecules, including novel angiogenic drugs, growth factors, chaperone proteins and cytokines, according to VFrontier Pharma: Systemic Lupus Erythematosus - Identifying and Commercializing First-in-Class Innovation report
This report states that first-in-class programs constitute an estimated 27% of the entire psoriasis pipeline, and are predominantly composed of targeted therapies, including cytokine and receptor modulators, nuclear receptor modulators and intracellular kinase inhibitors.
Senior Analyst says: There are several novel therapies targeting first-in-class T cell antigens, thanks to a growing understading of the signaling pathways underlying the psoriasis pathophysiology, in which T cell have been shown to play a substantial role in disease progression.
Therapies that can selectively modulate specific subsets of immune cells, without compromising the entire immune system, have become increasingly desirable, according to Publisher. One such program is Tregalizumab, a humanized Cluster of Differentiation (CD) 4-specific monoclonal antibody.
Senior Analyst says: “In contrast to other anti-CD4 antibodies, Tregalizumab is able to activate the suppressive properties of regulatory T cells. It is currently in Phase II clinical trials for the treatment of rheumatoid arthritis and in Preclinical development for treating psoriasis.”
Publisher states that although no preclinical or clinical efficacy data has been disclosed for the antibody, it has been involved in a lucrative co-development deal worth $480 million between Biotest and Abbott Laboratories.
Other promising psoriasis therapies are targeting novel angiogenic signaling molecules at the psoriatic plaque level, as topical therapies. This has been validated in a small scale, double-blind and randomized clinical study, according to Publisher.
With further validation in larger scale clinical studies, insulin receptor substrate-1 inhibitors may prove to be a novel localized therapy for psoriasis, which can be used in conjunction with systemic treatments.
Frontier Pharma: Psoriasis - Identifying and Commercializing First-in-Class Innovation report was built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis conducted by Publisher’s team of industry experts.
See Table of Content and purchase this publication at: http://www.marketresearchreports.com/gbi-research/frontier-pharma-systemic-lupus-erythematosus-identifying-and-commercializing-first
About Market Research Reports, Inc.
Market Research Reports, Inc. is the world's leading source for market research reports and market data. We provide you with the latest market research reports on global markets, key industries, leading companies, new products and latest industry analysis & trends.
For Business and Industry News visit http://www.marketresearchtimes.com